SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Haemonetics Corp – ‘8-K’ for 3/2/21

On:  Tuesday, 3/2/21, at 9:37pm ET   ·   As of:  3/3/21   ·   For:  3/2/21   ·   Accession #:  1104659-21-31001   ·   File #:  1-14041

Previous ‘8-K’:  ‘8-K’ on / for 3/1/21   ·   Next:  ‘8-K’ on 3/5/21 for 3/2/21   ·   Latest:  ‘8-K’ on / for 4/19/21

Magnifying glass tilted right emoji
 
  in    Show  and   Hints

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 3/03/21  Haemonetics Corp                  8-K:7,9     3/02/21   11:207K                                   Toppan Merrill/FA

Current Report   —   Form 8-K   —   Sect. 13 / 15(d) – SEA’34
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 8-K         Current Report                                      HTML     27K 
 2: EX-99.1     Miscellaneous Exhibit                               HTML     17K 
 7: R1          Cover                                               HTML     46K 
 9: XML         IDEA XML File -- Filing Summary                      XML     11K 
 6: XML         XBRL Instance -- tm218226d2_8k_htm                   XML     15K 
 8: EXCEL       IDEA Workbook of Financial Reports                  XLSX      6K 
 4: EX-101.LAB  XBRL Labels -- hae-20210302_lab                      XML     96K 
 5: EX-101.PRE  XBRL Presentations -- hae-20210302_pre               XML     64K 
 3: EX-101.SCH  XBRL Schema -- hae-20210302                          XSD     12K 
10: JSON        XBRL Instance as JSON Data -- MetaLinks               25±    33K 
11: ZIP         XBRL Zipped Folder -- 0001104659-21-031001-xbrl      Zip     15K 


‘8-K’   —   Current Report


This is an HTML Document rendered as filed.  [ Alternative Formats ]



 iX:   C:   C:   C:   C:   C:   C:   C:   C: 
 i 0000313143  i false 0000313143 2021-03-02 2021-03-02 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

 

Form  i 8-K

 

 

 

Current Report

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported):  i March 2, 2021

 

 

 

 i HAEMONETICS CORPORATION

(Exact name of registrant as specified in its charter)

 

 

 

Commission File Number:  i 001-14041

 

 i Massachusetts    i 04-2882273

(State or other jurisdiction

of incorporation)

 

(IRS Employer

Identification No.)

 

 i 125 Summer Street

 i Boston,  i MA  i 02110

(Address of principal executive offices, including zip code)

 

 i 781- i 848-7100

(Registrant’s telephone number, including area code)

 

(Former name or former address, if changed since last report)

 

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

 i ¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 i ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 i ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 i ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading
Symbol(s)
  Name of each exchange
on which registered
 i Common Stock, $.01 par value per share    i HAE    i New York Stock Exchange

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company   i ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ¨

 

 

 C: 

 

 

 

Item 7.01 Regulation FD Disclosure.

 

On March 2, 2021, Haemonetics Corporation issued a press release announcing that it had priced an offering of $435 million aggregate principal amount of convertible senior notes due 2026 in a private offering pursuant to Rule 144A under the Securities Act of 1933, as amended. A copy of the press release is furnished as Exhibit 99.1 and incorporated herein by reference.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits.

 

Exhibit
No.
  Description
     
99.1   Press release of Haemonetics Corporation dated March 2, 2021
     
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 C: 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  HAEMONETICS CORPORATION
     
Date: March 2, 2021 By: /s/ Christopher A. Simon  
  Name:  Christopher A. Simon
  Title: President and Chief Executive Officer  

 

 C: 

 

 

 C: 

Dates Referenced Herein   and   Documents Incorporated by Reference

This ‘8-K’ Filing    Date    Other Filings
Filed as of:3/3/21None on these Dates
Filed on / For Period end:3/2/21
 List all Filings 
Top
Filing Submission 0001104659-21-031001   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2021 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Fri., Apr. 23, 12:38:02.2am ET